Literature DB >> 18206278

Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Darrell E Singer1, Rachel Schneerson, Christian T Bautista, Mark V Rubertone, John B Robbins, David N Taylor.   

Abstract

The seroconversion rates and geometric mean concentrations (GMC) of IgG anti-PA for stored sera from U.S. military personnel immunized 3, 4, and 6 times with the U.S. licensed anthrax vaccine adsorbed were studied. Anti-PA IgG concentrations were measured by ELISA. All 246 vaccinees had low but detectable pre-immunization anti-PA IgG (GMC 1.83 microg/mL). Three doses elicited a GMC of 59.92 microg/mL and a seroconversion rate of 85.3%, four doses elicited a GMC of 157.44 microg/mL and 67.9% and the sixth of 276.95 microg/mL and 45.5%, respectively. The forth dose elicited 100% seroconversion compared to the pre-immunization level. These results should facilitate comparison between different immunization schedules and new vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18206278      PMCID: PMC2268034          DOI: 10.1016/j.vaccine.2007.11.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.

Authors:  S Ashkenazi; J H Passwell; E Harlev; D Miron; R Dagan; N Farzan; R Ramon; F Majadly; D A Bryla; A B Karpas; J B Robbins; R Schneerson
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  In their own words: lessons learned from those exposed to anthrax.

Authors:  Janice C Blanchard; Yolanda Haywood; Bradley D Stein; Terri L Tanielian; Michael Stoto; Nicole Lurie
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

3.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Diphtheria immunization in young babies; a study of some factors involved.

Authors:  M BARR; A T GLENNY; K J RANDALL
Journal:  Lancet       Date:  1950-01-07       Impact factor: 79.321

5.  [The problem of interval in primary immunization consisting of several vaccinations].

Authors:  L Erdös
Journal:  Z Gesamte Hyg       Date:  1974-11

6.  Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults.

Authors:  M G Myers; C W Beckman; R A Vosdingh; W A Hankins
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

7.  Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies.

Authors:  Fabien Brossier; Martine Lévy; Annie Landier; Pierre Lafaye; Michèle Mock
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

8.  Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Authors:  Conrad P Quinn; Peter M Dull; Vera Semenova; Han Li; Shane Crotty; Thomas H Taylor; Evelene Steward-Clark; Karen L Stamey; Daniel S Schmidt; Kelly Wallace Stinson; Alison E Freeman; Cheryl M Elie; Sandra K Martin; Carolyn Greene; Rachael D Aubert; John Glidewell; Bradley A Perkins; Rafi Ahmed; David S Stephens
Journal:  J Infect Dis       Date:  2004-08-30       Impact factor: 5.226

9.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

10.  Neutralizing antibodies and persistence of immunity following anthrax vaccination.

Authors:  James F Hanson; Sarah C Taft; Alison A Weiss
Journal:  Clin Vaccine Immunol       Date:  2006-02
View more
  11 in total

1.  Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Authors:  Joseph A Bellanti; Feng-Ying C Lin; Chiayung Chu; Joseph Shiloach; Stephen H Leppla; German A Benavides; Arthur Karpas; Mahtab Moayeri; Chunyan Guo; John B Robbins; Rachel Schneerson
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

2.  Sortase-conjugation generates a capsule vaccine that protects guinea pigs against Bacillus anthracis.

Authors:  Gabriella Garufi; Ya-Ting Wang; So-Young Oh; Hannah Maier; Dominique M Missiakas; Olaf Schneewind
Journal:  Vaccine       Date:  2012-03-23       Impact factor: 3.641

3.  The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.

Authors:  N M Pajewski; S D Parker; G A Poland; I G Ovsyannikova; W Song; K Zhang; B A McKinney; V S Pankratz; J C Edberg; R P Kimberly; R M Jacobson; J Tang; R A Kaslow
Journal:  Genes Immun       Date:  2011-03-03       Impact factor: 2.676

4.  Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.

Authors:  David I Bernstein; Lisa Jackson; Shital M Patel; Hana M El Sahly; Paul Spearman; Nadine Rouphael; Thomas L Rudge; Heather Hill; Johannes B Goll
Journal:  Vaccine       Date:  2014-09-17       Impact factor: 3.641

5.  A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed.

Authors:  Nicholas M Pajewski; Sadeep Shrestha; Conrad P Quinn; Scott D Parker; Howard Wiener; Brahim Aissani; Brett A McKinney; Gregory A Poland; Jeffrey C Edberg; Robert P Kimberly; Jianming Tang; Richard A Kaslow
Journal:  Vaccine       Date:  2012-05-31       Impact factor: 3.641

6.  Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Haijing Hu; Stephen H Leppla; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

7.  Vaccine protection against Bacillus cereus-mediated respiratory anthrax-like disease in mice.

Authors:  So-Young Oh; Hannah Maier; Jay Schroeder; G Stefan Richter; Derek Elli; James M Musser; Lauriane E Quenee; Dominique M Missiakas; Olaf Schneewind
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

8.  Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Nicholas M Pajewski; Conrad P Quinn; Richard A Kaslow; Robert M Jacobson; Gregory A Poland
Journal:  Infect Immun       Date:  2013-05-06       Impact factor: 3.441

Review 9.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01

10.  Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Authors:  Brent J Yamamoto; Annette M Shadiack; Sarah Carpenter; Daniel Sanford; Lisa N Henning; Nestor Gonzales; Edward O'Connor; Leslie S Casey; Natalya V Serbina
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.